Collection |

Continuing Medical Education

This activity has been planned and implemented through the joint providership of Medscape, LLC and Springer Nature. Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at here; and (4) view/print certificate. 

Further CME papers from earlier years can be found on the Medscape website

2020

Learning Objectives Upon completion of this activity, participants will be able to: 1. Assess demographic risk factors for radiation retinopathy after I-125 plaque brachytherapy for uveal melanoma. 2. Analyze foveal avascular zone size in comparing eyes among patients treated for uveal melanoma. 3. Evaluate capillary density in comparing eyes among patients treated for uveal melanoma. Continuing Medical Education In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at www.medscape.org/journal/eye; (4) view/print certificate. Credit hours 1.0 Release date: Expiration date: November 23rd 2021 Post-test link: https://medscape.org/eye/posttest938103 Authors/Editors disclosure information S.S. has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Allergan, Inc.; Apellis; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Novartis; Oculis; Optos; Oxurion; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. T.E.d.C. and W.F.M. have disclosed no relevant financial relationships. Journal CME author disclosure information Charles P. Vega, MD, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: GlaxoSmithKline.

Article CME | | Eye

Learning Objectives Upon completion of this activity, participants will be able to: 1. Distinguish the most salient pathological feature of high myopia. 2. Evaluate the long-term tolerability of atropine eye drops for myopia. 3. Analyze the long-term efficacy of atropine eye drops for myopia. 4. Assess variables that might alter the efficacy of atropine eye drops for myopia. Continuing Medical Education In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at www.medscape.org/journal/eye; (4) view/print certificate. Credit hours 1.0 Release date: Expiration date: 21 September 2021 Post-test link: https://medscape.org/eye/posttest934752 Authors/Editors disclosure information Sobha Sivaprasad, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for: Allergan, Inc.; Apellis; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Novartis; Oculis; Optos; Oxurion; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. Jan Roelof Polling, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for: Théa Laboratories; Nevakar, Inc. Emily Tan, MD, has disclosed no relevant financial relationships. Sjoerd Driessen, MD, has disclosed no relevant financial relationships. Sjoukje E. Loudon, MD, has disclosed no relevant financial relationships. Hoi-Lam Wong, MD, has disclosed no relevant financial relationships. Astrid van der Schans, MD, PhD, has disclosed no relevant financial relationships. J. Willem Tideman, MD, has disclosed no relevant financial relationships. Caroline C. W. Klaver, MD, PhD, has disclosed the following relevant financial relationships: served as an advisor or consultant for: Bayer AG; Nevakar, Inc.; Novartis Pharmaceuticals Corporation; Théa Laboratories. Journal CME author disclosure information Charles P. Vega, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for: GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Served as a speaker or a member of a speakers bureau for: Genentech, Inc.; GlaxoSmithKline.

Article CME | Open Access | | Eye

Learning Objectives Upon completion of this activity, participants will be able to: 1. Assess the efficacy of off-the-shelf use of 2-diopter cylinder correction toric intraocular lenses in cataract surgery for patients with preoperative corneal astigmatism of 2.00 D or more, based on a prospective randomised study. 2. Evaluate the safety and patient-reported outcomes of off-the-shelf use of 2-diopter cylinder correction toric intraocular lenses in cataract surgery for patients with preoperative corneal astigmatism of 2.00 D or more, based on a prospective randomised study. 3. Determine the potential suitability of off-the-shelf use of toric intraocular lenses for more widespread adoption by the National Health Service or other large public health programs, and other clinical implications of their efficacy and safety, based on a prospective randomised study. Continuing Medical Education In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at www.medscape.org/journal/eye; (4) view/print certificate. Credit hours 1.0 Release date: July 30, 2020 Expiration date: July 30, 2021 Post-test link: https://medscape.org/eye/posttest929021 Authors/Editors disclosure information Sobha Sivaprasad, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for: Allergan, Inc.; Apellis; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Novartis; Oculis; Optos; Oxurion; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. Nick Stanojcic, BSc, MCOptom, FRCOphth, has disclosed no relevant financial relationships. Harry Roberts, MSc, FRCOphth, has disclosed the following relevant financial relationships: served as an advisor or consultant for: Alcon UK. Vijay Wagh, FRCOphth, has disclosed no relevant financial relationships. Bruno Zuberbuhler, PhD, FRCOphth, has disclosed no relevant financial relationships. David O'Brart, MD (Res), FRCOphth, FRCS, RefCert(RCOphth), has disclosed the following relevant financial relationships: received grants for clinical research from: Alcopn Inc., Rayner Ltd, Avedro Inc. Owns stock, stock options, or bonds from: Sparca Inc. Employed by a commercial interest: Sparca Inc.

Article CME | | Eye

Learning Objectives Upon completion of this activity, participants will be able to: 1. Describe symptomatic improvement after PPV for symptomatic floaters, according to results from a retrospective survey study. 2. Determine safety outcomes after PPV for symptomatic floaters, according to results from a retrospective survey study. 3. Identify clinical implications of the efficacy and safety of PPV for symptomatic floaters, according to results from a retrospective survey study. Accreditation statements In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit hours 1.0 Release date: Expiration date: 19 April 2020 Post-test link: https://medscape.org/eye/posttest924758 Authors/Editors disclosure information Sobha Sivaprasad, MD, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Optos; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. EOZ, MD, has disclosed no relevant financial relationships. BP, MD, has disclosed no relevant financial relationships. SO, MD, has disclosed no relevant financial relationships. SB, MD, has disclosed the following relevant financial relationships: served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation. RAA, MD, MPH, has disclosed no relevant financial relationships. FK, MD, has disclosed no relevant financial relationships. GG, MD, has disclosed no relevant financial relationships. AS, MD, has disclosed no relevant financial relationships. NA, MD, has disclosed no relevant financial relationships. Journal CME author disclosure information Laurie Barclay, MD, Freelance writer and reviewer, Medscape, LLC, and has disclosed no relevant financial relationships.

Article CME | | Eye

2018-2019

Learning Objectives Upon completion of this activity, participants will be able to:1.Describe morphological features of the parapapillary beta and gamma zone in eyes with CACG compared with nonmyopic control eyes, according to an observational cross-sectional study2.Determine factors associated with morphological features of the parapapillary beta and gamma zone, according to an observational cross-sectional study3.Identify pathophysiological implications of morphological features of the parapapillary beta and gamma zone in eyes with CACG, according to an observational cross-sectional study Accreditation Statements In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit Hours 1.0 Release date: 30 August 2019 Expiration date: 30 August 2020 Post-test link: https://medscape.org/eye/posttest915887 Authors/Editor disclosure information Sobha Sivaprasad has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Optos; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. Kunte Shang, MD, has disclosed no relevant financial relationships. Xinxin Hu, MD, has disclosed no relevant financial relationships. Yi Dai, MD, PhD, has disclosed no relevant financial relationships. Journal CME author disclosure information Laurie Barclay, MD, has disclosed no relevant financial relationships.

Article | | Eye

Learning Objectives Upon completion of this activity, participants will be able to: 1. Describe recorded cause of death and long-term melanoma-specific survival of patients with UM, according to an analysis of SOOS data 2. Determine long-term cancer-specific and all-cause survival of patients with UM, according to an analysis of SOOS data 3. Identify clinical implications of long-term all-cause and cause-specific survival of patients with UM, according to an analysis of SOOS data Continuing Medical Education In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit Hours 1.0 Release date: 25 October 2019 Expiration date: 25 October 2020 Post-test link: https://medscape.org/eye/posttest918527 Authors/Editors disclosure information S.S. has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Optos; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. A.J., L.B., M.S., V.C., P.C., and E.K. have disclosed no relevant financial relationships. Journal CME author disclosure information Laurie Barclay has disclosed no relevant financial relationships.

Article | | Eye

Learning objectives Upon completion of this activity, participants will be able to:1.Compare anatomical success rate between air and 20% SF6 tamponade in 27GPPV for RRD, according to a retrospective, observational, and consecutive study.2.Compare visual outcomes and changes in intraocular pressure during 12-month follow-up between air and 20% SF6 tamponade in 27GPPV for RRD, according to a retrospective, observational, and consecutive study.3.Compare type and frequency of complications during 12-month follow-up between air and 20% SF6 tamponade in 27GPPV for RRD, according to a retrospective, observational, consecutive study, and describe other clinical implications regarding surgical outcomes. Accreditation Statements In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit Hours 1.0 Release date: 20 December 2019 Expiration date: 20 December 2020 Post-test link: https://medscape.org/eye/posttest921555 Authors/Editors disclosure information A.T. has disclosed no relevant financial relationships. H.I. has disclosed the following relevant financial relationships: received grants for clinical research from: Alcon Japan. M.H. has disclosed no relevant financial relationships. K.O. has disclosed no relevant financial relationships. W. M. has disclosed no relevant financial relationships. A.M. has disclosed no relevant financial relationships. M.N. has disclosed the following relevant financial relationships: received grants for clinical research from: Alcon Japan; Otsuka Pharmaceuticals. Sobha Sivaprasad (Editor) has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Optos; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. Journal CME author disclosure information Laurie Barclay has disclosed no relevant financial relationships.

Article | | Eye

Learning Objectives Upon completion of this activity, participants will be able to:1.Describe the estimated lifetime benefit of gene therapy for the retinal dystrophy choroideremia, according to a Markov model of disease progression informed by clinical data of AAV.REP1 and voretigene neparvovec.2.Illustrate the effects of discount rate and sensitivity analysis on estimated lifetime benefit of gene therapy for choroideremia, according to a Markov model of disease progression informed by clinical data of AAV.REP1 and voretigene neparvovec.3.Identify clinical implications of the estimated lifetime benefit of gene therapy for choroideremia, according to a Markov model of disease progression informed by clinical data of AAV.REP1 and voretigene neparvovec. Continuing Medical Education In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit hours 1.0 Release date: 17 July 2019 Expiration date: 17 July 2020 Post-test link: https://medscape.org/eye/posttest913835 Authors/Editor disclosure information Sobha Sivaprasad has disclosed the following relevant financial relationships: Served as an advisor or consultant for Allergan, Bayer, Boehringer Ingelheim, Roche, Heidelberg, Optos. Served as a speaker or a member of a speakers bureau for Bayer, Allergan, Novartis, Optos. Received grants for clinical research from: Bayer, Boehringer Ingelheim, Allergan, Novartis, Optos. REM has disclosed the following relevant financial relationships: Served as an advisor or consultant for Nightstar Therapeutics plc; Spark Therapeutics, Inc. Served as a speaker or a member of a speakers bureau for Nightstar Therapeutics plc. Received grants for clinical research from Nightstar Therapeutics plc. CLHH, JKJ, JAS, RPV, and DAB have disclosed no relevant financial relationships. Journal CME author disclosure information Laurie Barclay, MD: freelance writer and reviewer. Laurie Barclay, MD, has disclosed no relevant financial relationships.

Article | | Eye

Learning Objectives Upon completion of this activity, participants will be able to:1.Describe clinicopathological features of eyelid SGC in the ethnic Chinese population in Taiwan, according to a retrospective study2.Determine prognostic factors for eyelid SGC in the ethnic Chinese population in Taiwan, according to a retrospective study3.Compare the 7th and 8th editions of the AJCC staging system for diagnostic performance regarding the outcomes of local recurrence, regional lymph node metastasis, and tumor-related death, according to a retrospective study Continuing Medical Education In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Credit hours 1.0 Release date: 31 May 2019 Expiration date: 31 May 2020 Post-test link: https://medscape.org/eye/posttest912117 Authors/Editors disclosure information S.S. has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Novartis Pharmaceuticals Corporation; Optos; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. Y.H., C.-Y.Y., Y.-H.W., L.-W.C., S.-L.L. have disclosed no relevant financial relationships. Journal CME author disclosure information Laurie Barclay has disclosed no relevant financial relationships.

Article | | Eye

Learning Objectives Upon completion of this activity, participants will be able to:1.Describe long-term progression of iERMs in eyes with good baseline visual acuity, according to a retrospective case series2.Determine predictors of visual decline in iERMs in eyes with good baseline visual acuity, according to a retrospective case series3.Explain factors associated with earlier surgical intervention for iERMs in eyes with good baseline visual acuity, according to a retrospective case series Continuing Medical Education In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at www.medscape.org/journal/eye; (4) view/print certificate. Credit hours 1.0 Release date: 19 April 2019 Expiration date: 19 April 2020 Post-test link: https://medscape.org/eye/posttest909693 Authors/Editors disclosure information S.S. has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Novartis Pharmaceuticals Corporation; Optos; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. L.S.M. has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Genentech, Inc.; IRIDEX Corporation. Served as a speaker or a member of a speakers bureau for: Genentech, Inc.; IRIDEX Corporation. Received grants for clinical research from: Genentech, Inc. S.S.P. has disclosed the following relevant financial relationships: Received grants for clinical research from: Allergan, Inc.; Roche/Novartis Pharmaceuticals Corporation. G.Y. has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Alimera Sciences; Allergan, Inc.; Carl Zeiss Meditec; IRIDEX Corporation. Received grants for clinical research from: Alcon Laboratories, Inc.; IRIDEX Corporation. K-Y.L., T.K., A.Y., L.M., B.P.D-J., A.M. have disclosed no relevant financial relationships. Journal CME author disclosure information Laurie Barclay has disclosed no relevant financial relationships.

Article | | Eye

Learning Objectives Upon completion of this activity, participants will be able to:1.Assess the incidence and demographic profile of patients presenting with OSSN in the United Kingdom during a 12-month period, based on a prospective observational study.2.Evaluate the clinical presentation of and risk factors associated with OSSN in the United Kingdom during a 12-month period, based on a prospective observational study.3.Determine management and prognosis of OSSN in the UK during a 12-month period, based on a prospective observational study. Continuing Medical Education In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at www.medscape.org/journal/eye; (4) view/print certificate. Credit hours 1.0 Release date: 28 December 2018; Expiration date: 28 December 2019 Post-test link: https://medscape.org/eye/posttest902113 Authors/Editor disclosure information Sobha Sivaprasad has disclosed the following relevant financial relationships: Served as an advisor or consultant for Allergan, Bayer, Boehringer Ingelheim, Novartis, Heidelberg, Optos. Served as a speaker or a member of a speakers bureau for Bayer, Allergan, Novartis, Optos. Received grants for clinical research from Bayer, Boehringer Ingelheim, Allergan, Novartis, Optos. H.H. has disclosed the following relevant financial relationships: Served as a speaker or a member of a speakers bureau for Alcon, Alimera, Bausch and Lomb, Bayer AG. C.A.K., R.M.K.S., S.S., S.B.K., and B.D. have disclosed no relevant financial relationships. Journal CME author disclosure information Laurie Barclay has disclosed the following relevant financial relationships: Owns stock, stock options, or bonds from: Pfizer Inc.

Article | | Eye

2016-2017